(Q45083749)

English

Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.

scientific article published on 11 April 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

0 references

1 reference

based on heuristic

inferred from title

Crohn's disease

1 reference

based on heuristic

inferred from title

Hirotsugu Imaeda

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Hirotsugu Imaeda

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Kenichiro Takahashi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Takehide Fujimoto

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Shigeki Bamba

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Tomoyuki Tsujikawa

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Masaya Sasaki

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Yoshihide Fujiyama

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Akira Andoh

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

11 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

49

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

100-109

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Evolving paradigms in the pathogenesis of IBD.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Assessing response and loss of response to biological therapies in IBD.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâ s disease after failure of two other anti-TNF antibodies

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1007%2FS00535-013-0803-4

21 January 2018

Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23575576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23575576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23575576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/23575576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23575576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23575576

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00535-013-0803-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

release_v4ioczmvf5cdpjjic45y6fl7da

1 reference

https://api.fatcat.wiki/v0/release/v4ioczmvf5cdpjjic45y6fl7da

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23575576%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45083749&oldid=2033001960"